Comparative Pharmacology
Head-to-head clinical analysis: ALPHAGAN versus CLONIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAGAN versus CLONIDINE HYDROCHLORIDE.
ALPHAGAN vs CLONIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Alpha-2 adrenergic agonist; centrally acting antihypertensive that reduces sympathetic outflow from the CNS, decreasing peripheral resistance, heart rate, and blood pressure.
1 drop of 0.1% or 0.15% solution in the affected eye(s) three times daily, approximately 8 hours apart.
Initial 0.1 mg orally twice daily; maintenance 0.2-0.6 mg/day in divided doses; maximum 2.4 mg/day. Also available as transdermal patch: 0.1-0.3 mg/day applied every 7 days.
None Documented
None Documented
2.5-3.0 hours in adults; in renal impairment, half-life is prolonged (up to 6 hours).
Terminal half-life: 12-16 hours (range 6-20 hours); prolonged in renal impairment (up to 40 hours).
Renal: approximately 70-80% as unchanged drug and metabolites; fecal: 5-10%.
Renal: 40-60% unchanged; hepatic metabolism to inactive metabolites (about 50%); fecal: minimal (<5%).
Category C
Category A/B
Alpha-2 Agonist
Alpha-2 Agonist